Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning
In Vitro Cellular & Developmental Biology - Animal · 2024
DOI: 10.1007/s11626-024-00983-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vitro Cellular & Developmental Biology - Animal, 2024. Verfasst von Rei Noguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. Hauptthemen laut MEDLINE: Drug Repositioning, Protein Kinase Inhibitors, Proteomics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Japan Medical Women's Association.
Abstract (Originalsprache)
Drug repositioning of approved drugs offers advantages over de novo drug development for a rare type of cancer. To efficiently identify on-target drugs from clinically successful kinase inhibitors in cancer drug repositioning, drug screening and molecular profiling of cell lines are essential to exclude off-targets. We developed a pharmacoproteogenomic approach to identify on-target kinase inhibitors, combining molecular profiling of genomic features and kinase activity, and drug screening of patient-derived cell lines. This study examined eight patient-derived giant cell tumor of the bone (GCTB) cell lines, all of which harbored a signature mutation of H3-3A but otherwise without recurrent copy number variants and mutations. Kinase activity profiles of 100 tyrosine kinases with a three-dimensional substrate peptide array revealed that nine kinases were highly activated. Pharmacological screening of 60 clinically used kinase inhibitors found that nine drugs directed at 29 kinases strongly suppressed cell viability. We regarded ABL1, EGFR, and LCK as on-target kinases; among the two corresponding on-target kinase inhibitors, osimertinib and ponatinib emerged as on-target drugs whose target kinases were significantly activated. The remaining 26 kinases and seven kinase inhibitors were excluded as off-targets. Our pharmacoproteomic approach enabled the identification of on-target kinase inhibitors that are useful for drug repositioning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
- Department of Patient-Derived Cancer Model, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
- Department of Oncopeptidomics, Tochigi Cancer Center; 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
- Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
- Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. takondo@ncc.go.jp.
Förderung
- Japan Medical Women's Association
Zitieren
APA
Noguchi, R., Osaki, J., Ono, T., Adachi, Y., Iwata, S., Yoshimatsu, Y., Sasaki, K., Kawai, A., & Kondo, T. (2024). Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning. In Vitro Cellular & Developmental Biology - Animal. https://doi.org/10.1007/s11626-024-00983-3
Vancouver
Noguchi R, Osaki J, Ono T, Adachi Y, Iwata S, Yoshimatsu Y, et al. Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning. In Vitro Cellular & Developmental Biology - Animal. 2024. doi:10.1007/s11626-024-00983-3
BibTeX
@article{Noguchi2024,
author = {Noguchi, Rei and Osaki, Julia and Ono, Takuya and Adachi, Yuki and Iwata, Shuhei and Yoshimatsu, Yuki and Sasaki, Kazuki and Kawai, Akira and Kondo, Tadashi},
title = {Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning},
journal = {In Vitro Cellular & Developmental Biology - Animal},
year = {2024},
doi = {10.1007/s11626-024-00983-3}
}
EUVIMED